{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:27:44Z","timestamp":1786429664557,"version":"build-2736575974"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021068","name":"Universidad de Las Am\u00e9ricas Ecuador","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by unlocking antitumor T-cell responses across multiple cancer types. However, a subset of patients experience rapid acceleration of disease progression shortly after ICI initiation, a phenomenon termed hyperprogressive disease (HPD). Although HPD remains clinically heterogeneous, emerging evidence suggests that HPD is not solely a stochastic anomaly, but may result from an immune rewiring failure triggered by checkpoint release in chronically inflamed, myeloid-dominated, or tolerogenic host organs that are permissive for tumor growth. Mechanistic studies in metabolic dysfunction-associated steatohepatitis (MASH)-associated hepatocellular carcinoma show that PD-1 blockade can fail to restore effective antitumor immunity and instead exacerbate pathogenic T-cell-mediated injury. Related findings in colitis-associated colorectal cancer, chronic lung inflammation, and glioblastoma suggest how pre-existing immune circuits shaped by inflammation, fibrosis, metabolic dysfunction, or immune privilege can constrain productive immune rewiring. We synthesize these organ-specific archetypes into an organ-context model in which ICIs act not by generating\n                    <jats:italic>de novo<\/jats:italic>\n                    immunity, but by amplifying pre-existing immune programs. In this model, checkpoint release may lead to either productive tumor control or maladaptive activation and accelerated progression, depending on the baseline immune architecture of the host tissue. Understanding HPD through the lens of organ-context immune wiring has major translational implications for predictive biomarkers, stratification strategies, and the design of context-aware immunotherapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1823041","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:00Z","timestamp":1786426500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Can tissue immune states shape the risk of hyperprogressive disease?"],"prefix":"10.3389","volume":"17","author":[{"given":"Iv\u00e1n M.","family":"Moya","sequence":"first","affiliation":[{"name":"Cancer Research Group, School of Biotechnology, Faculty of Engineering and Applied Sciences, Universidad de Las Am\u00e9ricas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz123","article-title":"Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111699","article-title":"Hyperprogressive disease during anti-PD-1 (PDCD1) \/ PD-L1 (CD274) therapy: a systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1634","article-title":"Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer","volume":"6","author":"Kas","year":"2020","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2226","article-title":"Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria","volume":"26","author":"Matos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-1390","article-title":"Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0636","article-title":"Hyperprogression and immune checkpoint inhibitors: hype or progress","volume":"25","author":"Adashek","year":"2020","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073736","article-title":"Hyperprogressive disease: main features and key controversies","volume":"22","author":"Arasanz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112949","article-title":"Hyperprogression, a challenge of PD-1\/PD-L1 inhibitors treatments: potential mechanisms and coping strategies","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13046-020-01721-9","article-title":"Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know","volume":"39","author":"Camelliti","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-13-2534","article-title":"IL-17A produced by \u03b3\u03b4 T cells promotes tumor growth in hepatocellular carcinoma","volume":"74","author":"Ma","year":"2014","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.15761\/ICST.1000334","article-title":"Immune-checkpoint inhibitor anti-PD1 aggravates colitis-associated colorectal cancer without enhancing intestinal inflammation","volume":"7","author":"Collard","year":"2020","journal-title":"Integr Cancer Sci Therap"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune system","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00849-2","article-title":"Does tissue imprinting restrict macrophage plasticity","volume":"22","author":"Guilliams","year":"2021","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a037960","article-title":"Decoding tissue-residency: programming and potential of frontline memory T cells","volume":"13","author":"Park","year":"2021","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.247","article-title":"Skin-resident T cells: the ups and downs of on site immunity","volume":"130","author":"Clark","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils dominate the immune cell composition in non-small cell lung cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)","volume":"28","author":"Galea","year":"2007","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0445-9","article-title":"Antigen-specific immune tolerance in the liver","volume":"3","author":"Doherty","year":"2019","journal-title":"Nat BioMed Eng"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.717601","article-title":"Tumor immune microenvironment landscape in glioma identifies a prognostic and immunotherapeutic signature","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.5","article-title":"Immunological functions of liver sinusoidal endothelial cells","volume":"13","author":"Knolle","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000000729","article-title":"PDCD4 deficiency aggravated colitis and colitis-associated colorectal cancer via promoting IL-6\/STAT3 pathway in mice","volume":"22","author":"Wang","year":"2016","journal-title":"Inflammation Bowel Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0948","article-title":"CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma","volume":"31","author":"Qin","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03064-6","article-title":"Chronic intestinal inflammation drives colorectal tumor formation triggered by dietary heme iron in vivo","volume":"95","author":"Seiwert","year":"2021","journal-title":"Arch Toxicol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-025-01753-3","article-title":"CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8(+) T cell exhaustion in colorectal cancer","volume":"27","author":"Zheng","year":"2025","journal-title":"Nat Cell Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12935-026-04177-7","article-title":"Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors","volume":"26","author":"Keivany","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-023-00927-2","article-title":"Immune checkpoint inhibitors in pMMR\/MSS colorectal cancer","volume":"54","author":"El Hajj","year":"2023","journal-title":"J Gastrointestinal Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201704-0795OC","article-title":"Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer","volume":"197","author":"Mark","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-214","article-title":"Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors","volume":"10","author":"Zhou","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627557","article-title":"The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108700","article-title":"Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: a systematic review and meta-analysis","volume":"207","author":"Zhang","year":"2025","journal-title":"Lung Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"17145","DOI":"10.1038\/s41598-025-02251-0","article-title":"COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors","volume":"15","author":"Boudoussier","year":"2025","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04881-2","article-title":"Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions","volume":"171","author":"Badani","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"31382","DOI":"10.1038\/s41598-024-82903-9","article-title":"Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.014","article-title":"Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function","volume":"49","author":"Buchan","year":"2018","journal-title":"Immunity"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-22-0699","article-title":"Combinatorial immunotherapy with agonistic CD40 activates dendritic cells to express IL12 and overcomes PD-1 resistance","volume":"11","author":"Krykbaeva","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-18-0061","article-title":"A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1737187","article-title":"Editorial: Advances in myeloid cell targeting for overcoming tumor immunosuppression","volume":"16","author":"Yan","year":"2025","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393925","article-title":"Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Pei","year":"2024","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110019","article-title":"Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors: a pooled analysis of 44 retrospective studies","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-22-0041","article-title":"Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after PD-1 blockade therapy","volume":"10","author":"Wakiyama","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004849","article-title":"iRECIST and atypical patterns of response to immuno-oncology drugs","volume":"10","author":"Ramon-Patino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.12.47","article-title":"Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment","volume":"11","author":"Onesti","year":"2019","journal-title":"J Thorac Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:01Z","timestamp":1786426501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2026.1823041"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1823041","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1823041"}}